马上注册，阅读更多内容，享用更多功能！
您需要 登录 才可以下载或查看，没有账号？立即注册 
×
Li G, Liu C, Xi P, Hou L, Xia Y, Qi Y, Pan W, Bai W, Li X, Zhou H, Li P, Song Z, Zhao H, Liu X. Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study. Lung Cancer. 2026 Jan;211:108883. doi: 10.1016/j.lungcan.2025.108883. Epub 2025 Dec 17. PMID: 41421036.
Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study - ScienceDirect
- Largest real-world comparison (N=463) of neoadjuvant chemoimmunotherapy vs. PACIFIC regimen in stage III NSCLC.
- NEO group showed superior median PFS (25.0 vs. 16.3 mo, HR=0.57) and OS (NR vs. 41.1 mo, HR=0.54).
- Survival benefit confirmed after propensity score matching and multivariable adjustment.
- Comparable grade ≥2 pneumonitis. A non-significant trend for higher grade ≥3 events in NEO group.
- Supports testing neoadjuvant immunotherapy in phase III trials for unresectable stage III NSCLC.
|
